Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
Insilico Medicine, the Hong Kong-based AI drug discovery company that went public on the Hong Kong Exchange in December 2025, has launched PandaClaw — an agentic AI system purpose-built for biologists working on therapeutic discovery. The tool is live inside Insilico's PandaOmics platform, with academic pricing published at $199 per month, distinguishing it from the many AI tooling announcements that amount to little more than a landing page and a waitlist.
PandaClaw is not a proprietary black box. It is built on LangChain and LangGraph, operates within an isolated sandbox environment for self-correction, and draws on three architectural layers: an Agent Core, a Data Warehouses layer, and a Skills library packing more than 140 scientific capabilities and 1,000-plus bioinformatics tools. The system's underlying data layer — 1.3 million omics samples, 47 million publications, 5.5 million patents — was described in a Journal of Chemical Information and Modeling paper co-authored by Frank Pun, Insilico's Hong Kong office head, who is serving as spokesperson for the PandaClaw launch.
The credibility question for any AI drug discovery tool is whether the underlying system has produced real results. For Insilico, that anchor is rentosertib, a TNIK inhibitor discovered using PandaOmics' target identification pipeline. The compound completed a Phase IIa trial in idiopathic pulmonary fibrosis (IPF) patients, showing a +98.4 mL gain in forced vital capacity versus a -20.3 mL decline in the placebo arm across 71 patients, according to results published in Nature Medicine in June 2025. It is, by Insilico's characterization, the first AI-discovered drug to complete Phase IIa. The trial was conducted in China and there were seven discontinuations due to liver injury — caveats that belong in any accounting of the result, but the headline finding is real and published.
The timing of the launch is not neutral. Insilico listed on the HKEX on December 30, 2025. The company's financial results call is scheduled for March 30, one week from today. PandaClaw's launch in the days ahead positions it as a flagship capability in the investor-facing narrative around the company's progress toward commercialization. Frank Pun's name appearing on both the JCIM data paper and the launch announcement is part of that construction — the same researcher anchoring the science and the product story.
PandaClaw is not the whole story; it is one module in a broader architecture Insilico has been building in public. A February 2026 ACS Central Science paper co-authored with Eli Lilly — Lilly is also an Insilico cornerstone IPO investor — maps the full "prompt-to-drug" pipeline: PandaClaw handles biology and target discovery; Nach01, developed with Microsoft Discovery, handles chemistry optimization; InClinico handles clinical prediction. PandaClaw's launch is most accurately understood as a component release in a system that is now being marketed as an integrated suite.
One gap worth noting: Insilico does not name the underlying large language model powering PandaClaw. The architecture is documented, the results are published, but the model itself is unnamed. That is unusual in a space where competitors regularly lead with model capabilities. It may reflect a deliberate choice, a licensing arrangement, or something else entirely — the announcement is silent on the point.
PandaClaw is available now inside PandaOmics. Academic pricing is published. Enterprise pricing is not. The March 30 earnings call will be the next data point on how Insilico is translating its pipeline into revenue — and whether the "first AI-designed drug to reach Phase IIa" milestone translates into the kind of partner and licensing activity that makes an AI drug discovery company financially viable outside of a bull market for biotech IPOs.